unfractionated heparin

ApprovedSmall molecule

unfractionated heparin is one of 293 small molecule programs targeting Venous Thromboembolism. It is currently in Approved.

Indications

Total Trials

Active Trials

292

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismActive, not recruiting

Acute Chest SyndromeActive, not recruiting

Venous ThrombosisActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

Acute Myocardial InfarctionActive, not recruiting

ST Elevation Myocardial InfarctionActive, not recruiting

PneumoniaActive, not recruiting

SepsisActive, not recruiting

ThromboembolismActive, not recruiting

Deep Vein ThrombosisActive, not recruiting

Venous ThromboembolismPhase 3

Active, not recruiting

Acute Chest SyndromePhase 2

Active, not recruiting

Venous ThrombosisPhase 3

Active, not recruiting

Acute Coronary SyndromePhase 2

Active, not recruiting

Acute Myocardial InfarctionPhase 3

Active, not recruiting

ST Elevation Myocardial InfarctionApproved

Active, not recruiting

PneumoniaPhase 3

Active, not recruiting

SepsisPhase 3

Active, not recruiting

ThromboembolismPhase 3

Active, not recruiting

Deep Vein ThrombosisPhase 3

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

unfractionated heparin

GSK

Approved

5 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Aldactone

Pfizer

Preclinical

1 7

Nexavar

Bayer

Preclinical

1 8

Stivarga

Bayer

Preclinical

1 9

Aimovig

Amgen

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Extracorporeal Membrane Oxygenation

NCT06275555

Q2 2027

Post-ApprovalNot yet recruiting

Sepsis

NCT06375616

Q3 2027

Post-ApprovalRecruiting

Anticoagulation

NCT06442267

Q1 2029

N/ANot yet recruiting

Prolonged

NCT06861374

Clinical

Trials by Indication[1]

Anticoagulation7 trials

LMWH Infusion as Anticoagulation for Home HD

Unknown status·—·Phase 4·NCT02957877·12 enrolled

Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support

Recruiting·MMedical University of Vienna·Phase 4·NCT06442267·90 enrolled

Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI

Completed·RRegado Biosciences, Inc.·Phase 2·NCT00715455·26 enrolled

Show 4 more trials

Use of Tinzaparin for Anticoagulation in Hemodialysis

Completed·CChristine Ribic·Phase 4·NCT01930396·191 enrolled

Comparison of Citrate and Heparin Anticoagulation During Hemodialysis With MCO PES-PVP (Theranova) Membrane

Unknown status·MMarija Malgaj Vrečko·N/A·NCT04139525·32 enrolled

Comparison of Biocompatibility of Plasmapheresis Procedures With Citrate and Heparin Anticoagulation

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT05191290·15 enrolled

Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI

Completed·—·Phase 4·NCT03664180·2,989 enrolled

Percutaneous Coronary Intervention5 trials

How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention

Completed·LLiverpool Heart and Chest Hospital NHS Foundation Trust·Phase 4·NCT01519518·1,829 enrolled

Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)

Completed·MMomenta Pharmaceuticals, Inc.·Phase 2·NCT00543400·503 enrolled

Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00818753·53 enrolled

Show 2 more trials

The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention

Completed· Sanofi logo

Sanofi·Phase 2·NCT00133731·947 enrolled

The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study

Completed·RRobert Welsh·Phase 3·NCT00882635·44 enrolled

COVID-195 trials

Inhaled Heparin for Hospitalised COVID-19 Patients

Completed·—·Phase 2/3·NCT04635241·485 enrolled

CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19

Completed·UUniversity of Sao Paulo General Hospital·N/A·NCT04487990·118 enrolled

Unfractionated Heparin in COVID-19 and Non-COVID-19 Patients

Completed·LLeiden University Medical Center··NCT05509647·1,500 enrolled

Show 2 more trials

Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)

Withdrawn·—·Phase 2/3·NCT05184101

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

Terminated·WWeill Medical College of Cornell University·Phase 4·NCT04406389·14 enrolled

Sepsis4 trials

Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection

Unknown status·TThe Third Xiangya Hospital of Central South University·Phase 3·NCT04861922·100 enrolled

Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis

Completed·IIndonesia University·Phase 3·NCT02135770·115 enrolled

Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI

Not yet recruiting·SShen Lei·Phase 4·NCT06375616·156 enrolled

Show 1 more trial

A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00049777·2,000 enrolled

Extracorporeal Membrane Oxygenation3 trials

BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation

Recruiting·SSydney Local Health District·Phase 2·NCT05959252·80 enrolled

Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation

Recruiting·XXiaotong Hou·N/A·NCT06275555·154 enrolled

Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

Unknown status·LLegacy Health System·Phase 4·NCT03965208·34 enrolled

40 more indications

Venous Thromboembolism3 trials

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Completed· Bayer logo

Bayer·Phase 3·NCT01516814·40 enrolled

Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients

Terminated· Pfizer logo

Pfizer·Phase 4·NCT00445328·84 enrolled

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Completed· Bayer logo

Bayer·Phase 3·NCT01516840·60 enrolled

Thromboembolism3 trials

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)

Completed·MMcMaster University·Phase 3·NCT00182143·3,659 enrolled

Nadroparin for the Initial Treatment of Pulmonary Thromboembolism

Completed·—·Phase 4·NCT00796692·274 enrolled

The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Completed· GSK logo

GSK·Phase 3·NCT00981409·41 enrolled

Pulmonary Embolism3 trials

ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism

Completed·BBoston Scientific Corporation·Phase 3·NCT01166997·59 enrolled

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

Terminated·—·Phase 4·NCT03988842·4 enrolled

Low Dose Catheter Directed Thrombolysis for Acute Pulmonary Embolism

Unknown status·UUniversity of Aarhus·Phase 2·NCT03854266·60 enrolled

Deep Vein Thrombosis3 trials

AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients

Completed· Pfizer logo

Pfizer·Phase 3·NCT01780987·80 enrolled

The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Completed· GSK logo

GSK·Phase 3·NCT00911157·39 enrolled

Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00067093·1,452 enrolled

Pneumonia2 trials

Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection

Unknown status·MMassimo Girardis·Phase 3·NCT04528888·210 enrolled

Nebulised Heparin in Patients With COVID-19 Pneumonia

Unknown status·LLady Reading Hospital, Pakistan·Phase 2/3·NCT05255848·180 enrolled

Enoxaparin2 trials

Tirofiban and Enoxaparin in High Risk Coronary Intervention

Completed·—·Phase 4·NCT00790387·60 enrolled

Enoxaparin Versus Unfractionated Heparin in PCI

Completed·TTriemli Hospital·Phase 4·NCT00439855·2,100 enrolled

Anticoagulant2 trials

Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery

Completed· GSK logo

GSK··NCT01444612·4,068 enrolled

Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO

Completed·MMedical University of Vienna·Phase 2/3·NCT05226442·40 enrolled

Acute Coronary Syndrome2 trials

Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome

Terminated· Pfizer logo

Pfizer·Phase 4·NCT00435487·173 enrolled

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

Completed· Sanofi logo

Sanofi·Phase 2·NCT00317395·3,241 enrolled

Septic Shock2 trials

Heparin Anticoagulation in Septic Shock

Terminated·UUniversity of Manitoba·Phase 2·NCT03378466·178 enrolled

Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot

Completed·UUniversity of Manitoba·Phase 2·NCT01648036·76 enrolled

Randomized2 trials

Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH

Completed· Novartis logo

Novartis·Phase 3·NCT01651780·803 enrolled

The Randomized OPTIMAL-ACT Trial

Completed·MMayo Clinic·Phase 2·NCT03772613·180 enrolled

Prolonged2 trials

Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy

Not yet recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT06861374·2,400 enrolled

Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI

Completed·SShenyang Northern Hospital·N/A·NCT03822975·6,016 enrolled

Heart1 trial

Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm

Completed· GSK logo

GSK·Phase 2·NCT00911300·349 enrolled

Venous thrombosis1 trial

Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities

Completed·—·Phase 3·NCT00628576·99 enrolled

Trial1 trial

ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial

Terminated· Novartis logo

Novartis·Phase 3·NCT01913483·732 enrolled

Critically Ill Patients1 trial

Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.

Unknown status·UUniversity Hospital, Antwerp·Phase 4·NCT01228292·250 enrolled

Optical Coherence Tomography1 trial

Optical Coherence Tomography Guided Antithrombotic Treatment After Endovascular Thrombectomy of the Posterior Circulation

Unknown status·SSunnybrook Health Sciences Centre·N/A·NCT04121611·25 enrolled

Acute Chest Syndrome1 trial

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

Terminated·CCraig Seaman·Phase 2·NCT02098993·7 enrolled

ST Elevation Myocardial Infarction1 trial

Pretreatment With Unfractionated Heparin for ST Elevation Myocardial Infarction

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT05247424·600 enrolled

Bleeding1 trial

Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients

Completed·CClinica Mediterranea·Phase 3·NCT01465503·837 enrolled

Nebulization1 trial

Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS

Completed·—·Phase 3·NCT03465085·60 enrolled

TED1 trial

Reduced Dose of Unfractionated Heparin in Patients Undergoing PCI

Completed·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00735280·2,505 enrolled

Trauma1 trial

Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma

Terminated·—·Phase 3·NCT01773083·13 enrolled

Occlusion1 trial

Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial.

Unknown status·IInstituto Nacional de Cardiologia Ignacio Chavez·N/A·NCT04561648·1,988 enrolled

STEMI1 trial

Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial

Recruiting·CChen Jing·N/A·NCT07361783·6,294 enrolled

Acute Myocardial Infarction1 trial

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Completed·CCardiovascular Research Foundation, New York·Phase 3·NCT00433966·3,602 enrolled

Knee Replacement Surgery1 trial

Does Thinning the Blood During Surgery Prevent Blood Clots Following Total Knee Replacement Surgery

Completed·OOttawa Hospital Research Institute·Phase 4·NCT00253851·30 enrolled

Coronary Revascularization1 trial

Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

Terminated·KKaiser Permanente·Phase 3·NCT02448550·250 enrolled

Prevention of Thromboembolic Events1 trial

A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients

Completed· Novartis logo

Novartis·Phase 3·NCT00451412·3,254 enrolled

Pediatric1 trial

Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT03318393·30 enrolled

Hemodialysis1 trial

Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU

Completed·—·Phase 3·NCT01962116·405 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO

Completed·—·N/A·NCT04925167·20 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation

Unknown status·XXiaobo Yang, MD·Phase 2·NCT05555641·40 enrolled

Prospective1 trial

Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization

Unknown status·—·Phase 4·NCT04725201·188 enrolled

End Stage Renal Disease (ESRD)1 trial

A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03000673·32 enrolled

ESS1 trial

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

Completed·SStealth BioTherapeutics Inc.·Phase 1·NCT01513200·12 enrolled

Single Dose1 trial

The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated Heparin

Completed·KKristian Karstoft·Phase 4·NCT06174961·23 enrolled

Systemic1 trial

Biological and Clinical Measurements Following Systemic Leakage When a Citrate or Heparin Lock is Used

Completed·—·Phase 4·NCT02860299·76 enrolled

Household Contacts1 trial

Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children

Active, not recruiting·MMurdoch Childrens Research Institute·Phase 2/3·NCT05204550·506 enrolled

Anti-Xa Activity1 trial

Comparision Between Activated Partial Thromboplastin Time Versus Anti-Xa Activity in Heparin Monitoring

Unknown status·WWuhan Asia Heart Hospital·Phase 4·NCT03426982·700 enrolled

Unspecified2 trials

Heparin Dose for Radial Angiography

Completed·UUniversity of Alberta·Phase 4·NCT01634438·49 enrolled

Patients Preference With Self-Injection: The PRISM Study

Completed·HHamilton Health Sciences Corporation·Phase 4·NCT00253396·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 80 trial records for unfractionated heparin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — unfractionated heparin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for unfractionated heparin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GSK

unfractionated heparin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q1 2029

Trials by Indication[1]

Anticoagulation7 trials

Percutaneous Coronary Intervention5 trials

COVID-195 trials

Sepsis4 trials

Extracorporeal Membrane Oxygenation3 trials

Venous Thromboembolism3 trials

Thromboembolism3 trials

Pulmonary Embolism3 trials

Deep Vein Thrombosis3 trials

Pneumonia2 trials

Enoxaparin2 trials

Anticoagulant2 trials

Acute Coronary Syndrome2 trials

Septic Shock2 trials

Randomized2 trials

Prolonged2 trials

Heart1 trial

Venous thrombosis1 trial

Trial1 trial

Critically Ill Patients1 trial

Optical Coherence Tomography1 trial

Acute Chest Syndrome1 trial

ST Elevation Myocardial Infarction1 trial

Bleeding1 trial

Nebulization1 trial

TED1 trial

Trauma1 trial

Occlusion1 trial

STEMI1 trial

Acute Myocardial Infarction1 trial

Knee Replacement Surgery1 trial

Coronary Revascularization1 trial

Prevention of Thromboembolic Events1 trial

Pediatric1 trial

Hemodialysis1 trial

Safety and Efficacy1 trial

Efficacy and Safety1 trial

Prospective1 trial

End Stage Renal Disease (ESRD)1 trial

ESS1 trial

Single Dose1 trial

Systemic1 trial

Household Contacts1 trial

Anti-Xa Activity1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News